000070940 001__ 70940
000070940 005__ 20200108100346.0
000070940 0247_ $$2doi$$a10.1093/ijnp/pyx110
000070940 0248_ $$2sideral$$a106485
000070940 037__ $$aART-2018-106485
000070940 041__ $$aeng
000070940 100__ $$aBarcones, M.F.$$uUniversidad de Zaragoza
000070940 245__ $$aCardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis
000070940 260__ $$c2018
000070940 5060_ $$aAccess copy available to the general public$$fUnrestricted
000070940 5203_ $$aBackground: We aimed to investigate the state of cardiovascular risk/protection factors in early psychosis patients.
Methods: A total 119 subjects were recruited during the first year after their first episode of psychosis. Eighty-five of these subjects were followed during the next 6 months. Cardiovascular risk/protection factors were measured in plasma and co-variated by sociodemographic/clinical characteristics. Multiple linear regression models detected the change of each biological marker from baseline to follow-up in relation to clinical scales, antipsychotic medication, and pro-/antiinflammatory mediators.
Results: Glycosylated hemoglobin is a state biomarker in first episode of psychosis follow-up patients and inversely correlated to the Global Assessment of Functioning scale. We found opposite alterations in the levels of VCAM-1 and E-selectin in first episode of psychosis baseline conditions compared with control that were absent in the first episode of psychosis follow-up group. Adiponectin levels decreased in a continuum in both pathological time points studied. E-Selectin plasma levels were inversely related to total antipsychotic equivalents and adiponectin levels inversely co-related to the Global Assessment of Functioning scale. Finally, adiponectin levels were directly related to antiinflammatory nuclear receptor PPARy expression in first episode of psychosis baseline conditions and to proinflammatory nuclear factor nuclear factor kB activity in follow-up conditions, respectively.
Conclusions: Our results support the need for integrating cardiovascular healthcare very early after the first episode of psychosis.
000070940 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000070940 590__ $$a4.207$$b2018
000070940 591__ $$aCLINICAL NEUROLOGY$$b40 / 199 = 0.201$$c2018$$dQ1$$eT1
000070940 591__ $$aPSYCHIATRY$$b30 / 146 = 0.205$$c2018$$dQ1$$eT1
000070940 591__ $$aPHARMACOLOGY & PHARMACY$$b45 / 266 = 0.169$$c2018$$dQ1$$eT1
000070940 591__ $$aNEUROSCIENCES$$b73 / 266 = 0.274$$c2018$$dQ2$$eT1
000070940 592__ $$a1.846$$b2018
000070940 593__ $$aPharmacology$$c2018$$dQ1
000070940 593__ $$aPsychiatry and Mental Health$$c2018$$dQ1
000070940 593__ $$aPharmacology (medical)$$c2018$$dQ1
000070940 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000070940 700__ $$aMacDowell, K.S.
000070940 700__ $$aGarcía-Bueno, B.
000070940 700__ $$aBioque, M.
000070940 700__ $$aGutiirrez-Galve, L.
000070940 700__ $$aGonzález-Pinto, A.
000070940 700__ $$aParellada, M.J.
000070940 700__ $$aBobes, J.
000070940 700__ $$aBernardo, M.
000070940 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000070940 700__ $$aLeza, J.C.
000070940 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000070940 773__ $$g21, 5 (2018), 410-422$$pInt. j. neuropsychopharmacol.$$tInternational Journal of Neuropsychopharmacology$$x1461-1457
000070940 8564_ $$s134937$$uhttps://zaguan.unizar.es/record/70940/files/texto_completo.pdf$$yVersión publicada
000070940 8564_ $$s107624$$uhttps://zaguan.unizar.es/record/70940/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000070940 909CO $$ooai:zaguan.unizar.es:70940$$particulos$$pdriver
000070940 951__ $$a2020-01-08-09:30:09
000070940 980__ $$aARTICLE